As of Dec. 31, 2024, Purple Biotech had $8.2 million in cash and short-term deposits, which it expects will be sufficient to fund operations into mid-2026.
Purple Biotech raised approximately $2.8 million through a direct offering of American Depositary Shares to advance its oncology therapies.Quiver AI SummaryPurple Biotech Ltd. has successfully completed...
Your Only Digest of Market-Moving News and Rumours From High-Growth, Small Cap Stocks
Purple Biotech announces a registered direct offering of 472,668 American Depositary Shares, expecting gross proceeds of $2.8 million.Quiver AI SummaryPurple Biotech Ltd. announced a definitive agreement...
WealthyVC.com scans North America’s 10,000+ publicly listed stocks across all seven exchanges to find the market-moving news that matters. Our focus is on quality, liquid, growth-oriented companies in...
CM24 targets CEACAM1, a multi-functional membrane glycoprotein that plays a critical role in tumor invasiveness, metastasis, and immune evasion.
Purple Biotech reports progress in pancreatic cancer trial and biomarker findings, with financial results showing reduced losses.Quiver AI SummaryPurple Biotech Ltd., a clinical-stage company focused on...
REHOVOT, Israel, Aug. 04, 2022 (GLOBE NEWSWIRE) -- Purple Biotech Ltd. ("Purple Biotech", or the "Company") (NASDAQ/TASE: PPBT), a clinical-stage company...
Gil Efron appointed as Chief Executive Officer Isaac Israel to transition to advisor role, continue as Board member REHOVOT, Israel, July 14, 2022 ...
A Confirmed Partial Response in GEJ Patient, Stable Disease demonstrated in 75% of patients with mutated-KRAS colon cancer REHOVOT,...